Prescription Xultophy 100/3.6 is an injectable medication for people with type 2 diabetes to lower blood sugar. Xultophy is recommended along with a good diet and exercise regime.
Xultophy pens contains 2 proven medications in 1 injector. It provides 24 hour blood sugar control and lowers A1C significantly.
Xultophy pens are not the first line of treatment for diabetes. It is never used in type 1 diabetes or in children.
Follow carefully the instructions in the packaging and take exactly as required by your doctor. Do not adjust the Xultophy dose without your doctors instruction. Monitor and keep track of your blood sugar carefully and share your results with your doctor.
Inject Xultophy at the same time daily without regards to food. Dosing may change according your Xultophy results as your requirement may change depending upon stress, illness, weight changes, or any lifestyle, diet and exercise changes you make in your life. Other medicines may also alter your required dose of Xultophy. The maximum allowable dose is 50 units per day. Do not inject into a vein or muscle. Do not use with an insulin pump.
Do not share your Xultophy and do not take if you have low blood sugar.
In 2019, when comparing Xultophy pen price to USA Xultophy coupon price, InsulinHub was found to offer a discount of approximately 50% in Xultophy savings.
Buy Xultophy 100/3.6 pens from InsulinHub.com for the best Xultophy price.
Information about Xultophy 100/3.6 (Liraglutide / Degludec)
Xultophy 100/3.6 is a combination injectable medication used to manage type 2 diabetes. It combines two active ingredients: liraglutide (a GLP-1 receptor agonist) and degludec (an ultra-long-acting insulin). Xultophy is designed to improve blood sugar control in patients who have not achieved adequate glycemic control with diet, exercise, and other diabetes medications. It is typically used as part of a broader treatment plan to manage blood sugar levels over time.
Product Highlights
- Xultophy 100/3.6 is primarily prescribed to adults with type 2 diabetes to help manage blood glucose levels, particularly when diet, exercise, and other diabetes medications alone are not sufficient.
- It is used as an adjunct to diet and exercise to improve glycemic control, especially in patients who are inadequately controlled on basal insulin therapy or other injectable diabetes medications.
Key Ingredients
Key Benefits
- By combining a GLP-1 receptor agonist (liraglutide) and insulin (degludec), Xultophy provides comprehensive blood sugar management in a single daily injection, reducing the need for multiple injections.
- Degludec's ultra-long action provides stable and predictable basal insulin coverage over 24 hours, helping to minimize blood sugar fluctuations.
- Clinical trials have shown that Xultophy effectively lowers HbA1c (a measure of long-term blood glucose control) in patients with type 2 diabetes.
- Liraglutide is associated with weight loss, a benefit for many people with type 2 diabetes who are also managing weight-related concerns.
Direction of Use
- Xultophy is injected subcutaneously (under the skin) once daily. The typical starting dose is 16 units of Xultophy (which contains 16 units of degludec and 0.58 mg of liraglutide). The dose can be adjusted based on the patient's blood glucose levels and individual response.
- Typical injection sites are the abdomen, thigh, or upper arm. It should be injected into the fatty tissue (subcutaneous tissue), not into muscle or veins.
- If a dose is missed, take it as soon as you remember. If it’s close to the time for the next dose, skip the missed dose and take the next dose as usual. Do not double the dose.
Safety Concerns
- As with all insulin-based therapies, Xultophy can cause low blood sugar (hypoglycemia), especially if a dose of insulin is too high, meals are missed, or exercise is increased.
- Common side effects related to liraglutide include nausea, vomiting, and diarrhea. These are often temporary and may subside over time.
- There is a risk of pancreatitis (inflammation of the pancreas), which requires prompt medical attention if symptoms such as severe abdominal pain, nausea, and vomiting occur.
- Xultophy should be used cautiously in patients with renal impairment, as it can affect kidney function. Regular kidney monitoring is recommended.
- Animal studies have shown a potential link to thyroid tumors with liraglutide, though human data is limited. Use with caution in patients with a history of thyroid cancer.
- Some patients may notice redness, itching, or swelling at the injection site.
Avoid Xultophy 100/3.6 (Liraglutide / Degludec) If
- If you have a history of pancreatitis (inflammation of the pancreas), you should avoid using Xultophy, as it can increase the risk of this condition.
- Xultophy should not be used in people with a personal or family history of medullary thyroid cancer (MTC) or in patients with multiple endocrine neoplasia syndrome type 2 (MEN 2), as liraglutide has been associated with thyroid tumors in animal studies.
- Xultophy may not be suitable for people with severe kidney problems or end-stage renal disease.
- If you are allergic to liraglutide, degludec, or any other ingredients in Xultophy, it should be avoided.
This product requires special packaging to maintain its integrity during the shipping process. DO NOT USE THIS MEDICATION if the attached temperature indicator shows that the medication was exposed to temperatures below 2 degrees or above 8 degrees Celsius, and contact the pharmacy immediately.
